Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L bought 4,820,959 shares of the business's stock in a transaction on Friday, February 28th. The stock was bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Standard BioTools Trading Up 2.7 %
NASDAQ:LAB traded up $0.03 during trading hours on Friday, reaching $1.16. The company had a trading volume of 3,709,846 shares, compared to its average volume of 2,176,444. Standard BioTools Inc. has a 52 week low of $0.99 and a 52 week high of $3.04. The firm's 50 day moving average price is $1.52 and its 200-day moving average price is $1.78. The firm has a market cap of $431.82 million, a price-to-earnings ratio of -1.63 and a beta of 1.62.
Institutional Investors Weigh In On Standard BioTools
Hedge funds have recently modified their holdings of the business. Wolverine Trading LLC bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $27,000. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Standard BioTools during the 4th quarter valued at $29,000. Two Sigma Securities LLC bought a new stake in shares of Standard BioTools during the 4th quarter valued at $30,000. Nisa Investment Advisors LLC grew its position in shares of Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company's stock valued at $35,000 after acquiring an additional 14,732 shares during the period. Finally, Creative Planning bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $39,000. Institutional investors own 53.74% of the company's stock.
Wall Street Analyst Weigh In
Separately, KeyCorp downgraded shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.
View Our Latest Analysis on Standard BioTools
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Stories
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
